Rachel Stanton

Rachel Stanton

Managing Partner, opr Life

Rachel is a healthcare communications specialist with a decade’s experience supporting health clients ensure Australians can live well.

From facilitating or improving access to new medicines, helping advocates drive forward policy change, to behaviour change among communities, Rachel leads our LIFE Agency to improve lives. Rachel works with clients to bring the right mix of people and skills to teams that work tirelessly to shift the status quo – sooner rather than later.

Campaigns that put an issue on the agenda are one thing; those that engage stakeholders, table solutions and deliver results are what Rachel is proud to lead. Similarly, raising awareness and increasing understanding are necessary, but changing behaviour to improve self-care and empower patient champions is vital.

With a passion for stakeholder engagement, public affairs and media relations – and where true integration can cut through – Rachel has supported a range of pharmaceutical products at various stages in their lifecycle. Much of this has involved fostering relationships and truly partnering with key opinion leaders and not-for profit / consumer organisations. Rachel prides herself in understanding the challenges clients face and the opportunities for change, and then identifying the right strategy that can make significant inroads.

A large part of Rachel’s career has seen her championing the work of the health and medical research sector, as well as the not-for-profit community. The advances made that now allow local champions to deliver for Australian patients are what Rachel and the team are particularly proud of.

Specifically, Rachel has worked across a number of disease areas, including rare diseases, oncology, cardiovascular disease, arthritis, asthma, osteoporosis, pain and infectious diseases, while also working with those operating in the vaccine preventable disease space.

Her Industry clients have included AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, bioCSL, Genzyme, Glaxo-Smith Kline, Novartis and Seqirus. She has supported The Garvan Institute, Research Australia and the Medical Research Future Fund Action Group, as well as Pink Hope, The Lung Foundation and Rare Cancers Australia.

Rachel also has a strong track record in issues management and crisis communications.